亚洲伊人久久大香线蕉结合,国产欧美日韩中文久久,国产成人亚洲精品无码综合原创,熟妇人妻系列AV无码一区二区,久久精品国产亚洲AV高级一级,国产日韩久久免费福利网站,欧美色图一区二区三区,五月综合av成人毛片亚洲m

        Founded in September 2022, Jinwei Medical is a high-tech enterprise integrating R&D, production and sales of cardiovascular, cerebrovascular and peripheral vascular interventional devices. The company has more than 60 personnel, including more than 40 R&D personnel (6 PhDs and 25 masters), and the main members of the technical team are from well-known medical device companies, such as Boston Scientific, Medtronic, Lepu Medical, and APT Medical.

       In terms of clinical application, the company has carried out clinical research cooperation projects with the Department of Neurology, Department of Thoracic Medicine and Department of Vascular Surgery of the famous hospitals in China, such as Xiangya Hospital of Central South University, the Third Hospital of North China Medical University, Beijing Tiantan Hospital, Peking Union Medical College Hospital, etc. The scientific and technological achievements generated from the cooperation not only form the company's technological barriers and increase the company's accumulation of intellectual property rights, but also make the company's research and development of the products more in line with the market demand. The company's product pipeline covers a wide range respectively, in the coronary artery, peripheral vascular, electrophysiology and other fields have product layout, vascular intervention medical equipment varieties complete category.

      In the future, the company will take complete coronary access supplies and electrophysiology products as the leading products, and focus on the development of peripheral vascular and neurological interventional medical devices industry layout. The company has set up R&D centers and sales centers in Changsha, Hangzhou and Beijing respectively, and will build two production bases in Changsha and Jiaxing soon, and the company's products are expected to obtain registration certificates and launch market sales by the end of 2024. The company has always been adhering to the concept of "people-oriented, unity of knowledge and action", is committed to independent innovation and development in the field of cardiovascular and cerebrovascular minimally invasive interventions, the pursuit of safer and more efficient medical solutions, aiming to promote the development of excellence in human medicine and health.